By continuing to use the site, you will be treated as having given your consent for processing your personal data: cookies and user data using the Yandex.Metrika and liveinternet.ru metric programs to improve the site and for the purpose of statistical analysis. If you do not want your data to be processed, please leave the site
RU
News
20.06.2022
Biosintez launched production of ointment for wound infections
Biosintez launched production of ointment for wound infections
Biosintez (Sun Pharma manufacturing site) has launched production of the Dioxymet® BSZ medicinal product (INN:  hydroxymethylquinoxaline dioxide) in the form of a topical ointment with a dosage of 5%.
More detailed
27.05.2022
Chemist’s Day
Chemist’s Day
Today, as part of the Chemist's Day celebration, the Company held an award ceremony for its employees.
More detailed
29.04.2022
Meeting with students
Meeting with students
On March 23, Penza State University (PSU) hosted a large-scale meeting of our company with students of specialties of the Medical, Pedagogical and Polytechnic Institutes as part of the Career Day at PJSC “Biosintez”.
More detailed
18.02.2022
Biosintez launched production of a combined antidiabetic drug
Biosintez launched production of a combined antidiabetic drug
The drug contains two ingredients: glibenclamide and metformin. * Metformin and glibenclamide differ in mechanisms of action and complement each other's hypoglycemic activity.
More detailed
17.02.2022
Sun Pharma announced the launch of the “Brustel” drug
Sun Pharma announced the launch of the “Brustel” drug
Another OTC drug of the NSAID group - Brustel was added to the Sun Pharma's portfolio in Russia.
The drug composition includes ketoprofen and is released in the form of a topical gel at a maximum therapeutic dosage of 5%.
More detailed
29.12.2021
Happy New Year
Happy New Year
Dear friends! Happy New Year 2022!
More detailed
10.09.2021
Biosintez is planning to increase the production of sodium nucleinate
Biosintez is planning to increase the production of sodium nucleinate
Using its own substance, Biosintez is planning to increase the production of a sodium nucleinate-based immunomodulator.
More detailed
05.07.2021
Biosintez launched production of a combined antidiabetic drug
Biosintez launched production of a combined antidiabetic drug
The drug contains two ingredients: glibenclamide and metformin. * Metformin and glibenclamide differ in mechanisms of action and complement each other's hypoglycemic activity.
More detailed
25.03.2021
Biosintez received Gratitude for the development of exports
Biosintez received Gratitude for the development of exports
On March 24, 2021, as part of the ceremony of awarding the heads of exporting companies of the Penza Region following the results of 2020, the Gratitude of the Chairman of the Government of the Penza Region was presented to the staff of PJSC “Biosintez” for its invaluable contribution to the development of the Penza Region in terms of export supplies of Penza Region enterprises to foreign markets
More detailed